$2.99
2.45% today
Nasdaq, Apr 01, 06:41 pm CET
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$3.06
+0.26 9.29% 1M
+0.21 7.37% 6M
+0.68 28.57% YTD
+0.08 2.68% 1Y
-26.74 89.73% 3Y
-45.94 93.76% 5Y
-158.54 98.11% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.15 4.67%
ISIN
US68235C1071
Symbol
OCX
Sector

Key metrics

Market capitalization $87.51m
Enterprise Value $82.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 43.90
P/S ratio (TTM) P/S ratio 46.55
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 25.15%
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-23.25m
Free Cash Flow (TTM) Free Cash Flow $-21.23m
Cash position $8.64m
EPS (TTM) EPS $-4.40
P/E forward negative
P/S forward 85.38
EV/Sales forward 80.52
Short interest 1.60%
Show more

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Oncocyte Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Oncocyte Corporation forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Oncocyte Corporation forecast:

Buy
50%
Hold
50%

Financial data from Oncocyte Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1.88 1.88
25% 25%
100%
- Direct Costs 2.67 2.67
14% 14%
142%
-0.79 -0.79
7% 7%
-42%
- Selling and Administrative Expenses 12 12
3% 3%
651%
- Research and Development Expense 8.65 8.65
10% 10%
460%
-22 -22
5% 5%
-1,153%
- Depreciation and Amortization 1.56 1.56
7% 7%
83%
EBIT (Operating Income) EBIT -23 -23
4% 4%
-1,237%
Net Profit -61 -61
115% 115%
-3,227%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncocyte Corporation Stock News

Neutral
Seeking Alpha
8 days ago
OncoCyte Corporation (NASDAQ:OCX ) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - CSO Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham Mason Carrico - Stephens Gabby Woody Joining us today are Oncocyte President and CEO, Josh Ri...
Neutral
MCAP MediaWire
8 days ago
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.
Neutral
GlobeNewsWire
8 days ago
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte...
More Oncocyte Corporation News

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Joshua Riggs
Employees 49
Founded 2009
Website www.oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today